3D QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods

European Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2010, Pages 667-681

  Pan, Xulin ^a   Tan, Ninghua ^a   Zeng, Guangzhi ^a   Huang, Huoqiang ^a,b   Yan, He ^a,b  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cathepsin K; CoMFA; CoMSIA; Ketoamides

Indexed keywords

AMIDE; CATHEPSIN K INHIBITOR; KETOAMIDE DERIVATIVE; LIGAND; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; INTERMETHOD COMPARISON; OSTEOPOROSIS; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

AMIDES; CATHEPSIN K; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73549121066     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.11.010     Document Type: Article

References (27)

1. Altmann E., Green J., and Tintelnot-Blomley M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating p1′ substituents. Bioorg. Med. Chem. Lett. 13 (2003) 1997-2001
2. Gelb B.D., Shi G.P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996) 1236-1238
3. Alves M.F.M., Puzer L., Cotrin S.S., Juliano M.A., Juliano L., Brömme D., and Carmona A.K. S3 to S3′ subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. Biochem. J. 373 Pt 3 (2003) 981-986
4. Stoch S.A., and Wagner J.A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther. 83 (2008) 172-176
5. Gauthier J.Y., Chauret N., Cromlish W., Desmarais S., Duong L.T., Falgueyret J.-P., Kimmel D.B., Lamontagne S., Lger S., LeRiche T., Li C.S., Mass F., McKay D.J., Nicoll-Griffith D.A., Oballa R.M., Palmer J.T., Percival M.D., Riendeau D., Robichaud J., Rodan G.A., Rodan S.B., Seto C., Thrien M., Truong V.-L., Venuti M.C., Wesolowski G., Young R.N., Zamboni R., and Black W.C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18 (2008) 923-928
6. Altmann E., Aichholz R., Betschart C., Buhl T., Green J., Irie O., Teno N., Lattmann R., Tintelnot-Blomley M., and Missbach M. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 50 (2007) 591-594
7. Kumar S., Dare L., Vasko-Moser J.A., James I.E., Blake S.M., Rickard D.J., Hwang S.-M., Tomaszek T., Yamashita D.S., Marquis R.W., Oh H., Jeong J.U., Veber D.F., Gowen M., Lark M.W., and Stroup G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40 (2007) 122-131
8. Teno N., Miyake T., Ehara T., Irie O., Sakaki J., Ohmori O., Gunji H., Matsuura N., Masuya K., Hitomi Y., Nonomura K., Horiuchi M., Gohda K., Iwasaki A., Umemura I., Tada S., Kometani M., Iwasaki G., Cowan-Jacob S.W., Missbach M., Lattmann R., and Betschart C. Novel scaffold for cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 6096-6100
9. Altmann E., Aichholz R., Betschart C., Buhl T., Green J., Lattmann R., and Missbach M. Dipeptide nitrile inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 16 (2006) 2549-2554
10. Crane S.N., Black W.C., Palmer J.T., Davis D.E., Setti E., Robichaud J., Paquet J., Oballa R.M., Bayly C.I., McKay D.J., Somoza J.R., Chauret N., Seto C., Scheigetz J., Wesolowski G., Mass F., Desmarais S., and Ouellet M. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J. Med. Chem. 49 (2006) 1066-1079
11. Barrett D.G., Deaton D.N., Hassell A.M., McFadyen R.B., Miller A.B., Miller L.R., Payne J.A., Shewchuk L.M., Willard D.H., and Wright L.L. Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 15 (2005) 3039-3043
12. Marquis R.W., Ru Y., LoCastro S.M., Zeng J., Yamashita D.S., Oh H.J., Erhard K.F., Davis L.D., Tomaszek T.A., Tew D., Salyers K., Proksch J., Ward K., Smith B., Levy M., Cummings M.D., Haltiwanger R.C., Trescher G., Wang B., Hemling M.E., Quinn C.J., Cheng H.Y., Lin F., Smith W.W., Janson C.A., Zhao B., McQueney M.S., D'Alessio K., Lee C.P., Marzulli A., Dodds R.A., Blake S., Hwang S.M., James I.E., Gress C.J., Bradley B.R., Lark M.W., Gowen M., and Veber D.F. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. 44 (2001) 1380-1395
13. Zeng G.-Z., Pan X.-L., Tan N.-H., Xiong J., and Zhang Y.-M. Natural biflavones as novel inhibitors of cathepsin B and K. Eur. J. Med. Chem. 41 (2006) 1247-1252
14. Zeng G.-Z., Tan N.-H., Hao X.-J., Mu Q.-Z., and Li R.-T. Natural inhibitors targeting osteoclast-mediated bone resorption. Bioorg. Med. Chem. Lett. 16 (2006) 6178-6180
15. Pan X.-H., Tan N.-H., Zeng G.-Z., Han H.-J., and Huang H.-Q. 3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K. Bioorg. Med. Chem. 14 (2006) 2771-2778
16. Barrett D.G., Boncek V.M., Catalano J.G., Deaton D.N., Hassell A.M., Jurgensen C.H., Long S.T., McFadyen R.B., Miller A.B., Miller L.R., Payne J.A., Ray J.A., Samano V., Shewchuk L.M., Tavares F.X., Wells-Knecht K.J., Willard D.H., Wright L.L., and Zhou H.-Q.Q. P2-p3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 15 (2005) 3540-3546
17. Barrett D.G., Catalano J.G., Deaton D.N., Hassell A.M., Long S.T., Miller A.B., Miller L.R., Shewchuk L.M., Wells-Knecht K.J., Willard D.H., and Wright L.L. Potent and selective p2-p3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable p1', p1, and/or p3 substitutions. Bioorg. Med. Chem. Lett. 14 (2004) 4897-4902
18. Barrett D.G., Catalano J.G., Deaton D.N., Long S.T., McFadyen R.B., Miller A.B., Miller L.R., Wells-Knecht K.J., and Wright L.L. A structural screening approach to ketoamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 15 (2005) 2209-2213
19. Barrett D.G., Catalano J.G., Deaton D.N., Long S.T., Miller L.R., Tavares F.X., Wells-Knecht K.J., Wright L.L., and Zhou H.-Q.Q. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 14 (2004) 2543-2546
20. Catalano J.G., Deaton D.N., Long S.T., McFadyen R.B., Miller L.R., Payne J.A., Wells-Knecht K.J., and Wright L.L. Design of small molecule ketoamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 14 (2004) 719-722
21. Deaton D.N., Hassell A.M., McFadyen R.B., Miller A.B., Miller L.R., Shewchuk L.M., Tavares F.X., Willard D.H., and Wright L.L. Novel and potent cyclic cyanamide-based cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 1815-1819
22. Rush T.S., Grant J.A., Mosyak L., and Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 48 (2005) 1489-1495
23. Jones G., Willett P., and Glen R.C. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput. Aided Mol. Des. 9 (2005) 532-549
24. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
25. SYBYL Molecular Modeling System, Version 7.3, Tripos Inc., St. Louis, MO, 63144-2913.
26. Bostrom J., Greenwood J.R., and Gottfries J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J. Mol. Graph. Model. 21 (2003) 449-462
27. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146